Investors & Media

Ryvu Therapeutics has a track record of creating significant value for shareholders since its listing on the NewConnect market in 2011 and the subsequent IPO on the main market of Warsaw Stock Exchange in 2014. The company has delivered strong return on the combined $91M investment from private, public market investors, including over $36M raised in the Series I shares offering in July 2020.

Ryvu has been consequently demonstrating research progress, bringing novel drug candidates to the clinic, including SEL24 (MEN1703) initiating Phase II studies and RVU120 progressing through Phase I, as well as additionally raising over $88M in non-dilutive grant funding to support its research efforts.

We value investor communications very highly and we build our investor relationships on trust and transparency. Ryvu is audited by EY and is subject to regulatory oversight of the Polish Financial Supervisory Authority, under the European Union and the Polish laws. Ryvu technological expertise is validated by global partnerships with Merck KGaA, Galapagos, Exelixis, Menarini Group and Leukemia & Lymphoma Society.

In 2016, Ryvu has spun out its NALP3 inflammasome assets to NodThera, founded by life science investor, Epidarex Capital.  In total, the project aimed at the development of inflammasome inhibitors discovered by Ryvu and spun off to NodThera, has already raised over £80 million (over $98 million) of funding. Ryvu remains a shareholder in the Company. For more information about NodThera see: www.nodthera.com.

In July 2020, Ryvu Therapeutics has moved its entire operations to its new headquarters, newly built R&D Centre for Innovative Drugs, located at 2 Sternbacha Street, in Krakow.